

Is early energy supply to patients suffering from acute pancreatitis beneficial?

Submission date 08/11/2016	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 03/01/2017	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 07/01/2020	Condition category Digestive System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Acute pancreatitis is a serious condition where the pancreas becomes inflamed over a short period of time. Treatment usually involves admission to hospital where a feeding tube is inserted through the nose and into the stomach to provide patients with nutrients. This is known as enteral feeding. The aim of this study is to find out whether starting enteral feeding early is beneficial to patients with acute pancreatitis.

Who can participate?

Patients aged over 18 with acute pancreatitis

What does the study involve?

Participants are randomly allocated to one of two groups. Group A receives enteral feeding within 24 hours of admission to hospital. Group B receives no enteral feeding in the first 24 hours of hospital admission. Intravenous glucose (given into a vein) or total parenteral nutrition (all nutrients given directly into the bloodstream) are also provided if needed. Organ failure, death rates and pancreatic necrosis (infection), length of hospital stay and pain are measured in both groups daily during the study and at 1-month follow up.

What are the possible benefits and risks of participating?

There are no risks involved with early enteral feeding.

Where is the study run from?

University of Pécs (Hungary)

When is the study starting and how long is it expected to run for?

January 2017 to January 2020

Who is funding the study?

University of Pécs (Hungary)

Who is the main contact?

Prof. Peter Hegyi

p.hegyi@tm-pte.org

Contact information

Type(s)

Scientific

Contact name

Prof Peter Hegyi

Contact details

Szigeti Street 12

Pécs

Hungary

7624

+36 (0)703 751 031

p.hegyi@tm-pte.org

Additional identifiers

Protocol serial number

-

Study information

Scientific Title

High versus low energy administration in the early phase of acute pancreatitis: a multicentre randomized double-blind clinical trial

Acronym

GOULASH

Study objectives

Researchers showed that enteral feeding is beneficial compared to a nil per os diet not only in severe, but also in mild and moderate AP. This study will provide the first evidence concerning the necessity of early energy supply.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Medical Research Council – Scientific and Research Ethics Committee, 25/10/2016 - approval pending

Study design

Randomised controlled two-arm double-blind multicentre interventional study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Acute pancreatitis

Interventions

Patients suffering from acute pancreatitis are randomised by computer into two groups:

Group A: high energy administration after admission

Patients will receive a 10 Ch nasogastric (NG) or nasojejunal (NJ) feeding tube at admission

EN will immediately started as follows:

Day 0: (From admission until the start of EN (can be vary from 2-24 h)): calorie intake: 0 kcal/kg/day

Day 1: High Energy Enteral Tube Feed (1.5 kcal/ml) 30 kcal/kg/day (volume cannot exceed 60 ml/h)

Day 2: High Energy Enteral Tube Feed (1.5 kcal/ml) 30 kcal/kg/day

Day 3: until it is necessary: High Energy Enteral Tube Feed (1.5 kcal/ml) 30 kcal/kg/day

Group B: low energy administration after hospital admission

Patients will receive a 10 Ch nasogastric or nasojejunal feeding tube at admission

EN will immediately start

Day 0: (From admission until the start of EN (can be vary from 2-24 h)): calorie intake: 0 kcal/kg/day

Day 1: Zero Energy Enteral Tube Feed (0 kcal/ml) 1440 ml/day

Day 2: Step Up1 Energy Enteral Tube Feed (0.50 kcal/ml) 10 kcal/kg/day (volume cannot exceed 60ml/h)

Day 3: Step Up2 Energy Enteral Tube Feed (1.00 kcal/ml) 20 kcal/kg/day

Day 4 (if needed): Step Up3 Energy Enteral Tube Feed (1.25 kcal/ml) 25 kcal/kg/day

Day 5 (if needed): Step Up4 Energy Enteral Tube Feed (1.5 kcal/ml) 30 kcal/kg/day

Day 6 (if needed): Step Up5 Energy Enteral Tube Feed (1.5 kcal/ml) 30 kcal/kg/day

Day 7 (if needed): High Energy Enteral Tube Feed (1.5 kcal/ml) 30 kcal/kg/day

Zero Energy Enteral Tube Feed (100ml): Energy: 0 kcal (0 KJ), Protein 0g, Carbohydrate: 0g, Fat: 0g + Minerals: 134mg Sodium, 201mg Potassium, 34mg Magnesium, 4,872 g Chloride (0%E) (in this study the local institutional pharmacy will compose it in accordance with the Hungarian regulations)
308,9 mOsm/L.

Patient is counted as discharged from hospital/from the study when:

1. The total feeding was tolerated for 24h
2. No amylase/lipase level were elevated after total feeding
3. CRP level is less than 50 mg/L
4. Abdominal pain has completely resolved
5. No other pancreatitis-related complication requiring hospitalization is detected

One follow-up visit will take place 1 month after hospital discharge.

Severity (mild, moderate, severe), mortality and pancreatic necrosis are defined as primary endpoints, whereas several secondary endpoints such as length of hospitalization or pain, are determined to understand the finer differences between the groups. The general feasibility, safety and quality checks required for the highest quality evidence are performed.

Intervention Type

Procedure/Surgery

Primary outcome(s)

1. Multi organ failure persisting for more than 48h, measured by clinical assessment at admission, daily during the study and at 1-month follow up
3. Mortality, measured at admission, daily during the study and at 1-month follow up

Key secondary outcome(s)

1. Pancreatic necrosis, measured by CT at admission, daily during the study and at 1-month follow up
2. Nutrition related complications: diarrhoea, aspiration pneumonia, pneumothorax due to central TPN catheter placement, measured by clinical assessment at admission and daily during the study
3. Need for conversion from NG to NJ feeding tube, measured by clinical assessment at admission and daily during the study
4. Need for conversion from enteral nutrition (EN) to total parenteral nutrition (TPN), measured by clinical assessment at admission and daily during the study
5. Days until the start of total feeding, measured daily during the study
6. Use of antibiotics, measured daily during the study
7. Pain relapse, measured using the VAS scale daily during the study
8. C-reactive protein (CRP), measured by laboratory test daily during the study
9. White blood cell (WBC) count, measured by laboratory test daily during the study
10. Procalcitonin (PCT), measured by laboratory test daily during the study
11. Infection, measured by microbiological test daily during the study
12. Length of hospital stay, measured daily during the study
13. Need for ICU admission, measured at admission and daily during the study
14. Length of ICU therapy, measured at admission and daily during the study
15. Organ failure, measured at admission and daily during the study
16. Complications, measured at admission, daily during the study and at 1-month follow up
17. Costs calculation

Completion date

01/01/2023

Eligibility

Key inclusion criteria

1. Patients above 18 years of age
2. Diagnosed with acute pancreatitis on the basis of the "2 out of 3" rule of the IAP/APA guideline
3. Written informed consent form is signed

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Hospitalization 72 hours before admission
2. Abdominal pain >120 hours (5 days)
3. Delirium tremens
4. Child-Pugh C stage liver cirrhosis
5. AP due to malignancy
6. Already on artificial nutrition (enteral or parenteral nutrition)
7. Pregnancy
8. BMI above 40 or below 18
9. Age above 80
10. Ketoacidosis
11. Whenever CT with contrast is contraindicated

Date of first enrolment

01/02/2017

Date of final enrolment

01/12/2022

Locations**Countries of recruitment**

Hungary

Study participating centre

University of Pécs

Szigeti Street 12

Pécs

Hungary

7624

Sponsor information

Organisation

University of Pécs

ROR

<https://ror.org/037b5pv06>

Funder(s)

Funder type

University/education

Funder Name

University of Pécs

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Prof. Péter Hegyi MD (p.hegyi@tm-pte.org).

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	14/09/2017		Yes	No
Participant information sheet		18/11/2016	15/06/2017	No	Yes
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes